Human Trials

Human Trials

CTCAE Adverse Event Grading in Tigilanol Tiglate Trials: How EBC-46 Clinical Safety Is Measured

CTCAE v5.0 framework explained — how Common Terminology Criteria for Adverse Events grade severity in tigilanol tiglate (EBC-46) clinical trials.

Human Trials

Pharmacokinetic Profile of Tigilanol Tiglate: Cmax, AUC, and Half-Life in Phase I Studies

A look at published systemic exposure data for intratumoral tigilanol tiglate, what plasma concentration measurements have shown about local versus systemic drug distribution.

Human Trials

Tumour-Type Stratification in Tigilanol Tiglate Trials: How Cohorts Are Built

How tigilanol tiglate trials divide patients by tumour type, why stratification matters for interpreting response data, and what readers should look for in trial reports.

Human Trials

Injection Site Responses in Tigilanol Tiglate Trials: Local Reactions and Wound Healing Timelines

Characterising the local injection-site reaction and wound-healing sequence observed in Phase I and Phase II tigilanol tiglate trials, with veterinary product comparison.

Human Trials

EBC-46 Trial Adverse Event Profiles: Published Data on Tolerability Across Patient Cohorts

A neutral look at adverse events reported in published Phase I and Phase II EBC-46 trials, including injection-site reactions and what the overall tolerability picture shows.

EBC-46

Long-Term Follow-Up: Tigilanol Tiglate Recurrence Rates in Veterinary and Human Trials

What the published long-term follow-up data show for tigilanol tiglate in veterinary and human trials, and why supplement buyers should read it carefully.

Human Trials

Tumour Microenvironment Remodelling After EBC-46 Injection: What Biopsy Data From Human Trials Reveals

Analysis of published biopsy findings from EBC-46 human trials showing immune infiltration, vascular disruption, and tissue remodelling patterns post-injection.

Human Trials

Wound Healing Timelines in EBC-46 Clinical Trials: What Published Data Shows About Post-Treatment Recovery

Reviewing the wound healing data from published tigilanol tiglate clinical trials and what recovery timelines tell us about the treatment mechanism.

Human Trials

Patient-Reported Outcomes in Tigilanol Tiglate Trials: Quality of Life Beyond Tumour Shrinkage

How clinical researchers measure patient-reported outcomes in EBC-46 human trials and why quality of life data matters alongside tumour response metrics.

Human Trials

EBC-46 Tumour Response by Histology: Which Cancer Types Show the Most Promise in Published Data

Published EBC-46 trial data spans multiple tumour types. Comparing response rates by histology reveals which cancer subtypes have shown the strongest signals in Phase I and II studies.

Human Trials

Reading the EBC-46 Human Trial Readouts: What Phase I and Phase II Actually Tell Us

How to read published and disclosed data from QBiotics’ Phase I and ongoing Phase II studies of tigilanol tiglate in humans, without overreaching the evidence.

Human Trials

EBC-46 Human Trials Update: Phase I Safety Data and Phase II Progress in 2026

An evidence-based review of tigilanol tiglate human clinical trials, covering Phase I safety results and the expanding Phase II programme across multiple tumour types.